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In this study, we analyzed 53 oral squamous-cell carcinomas 
among Indians for the presence of alterations in the tumor- 
suppressor gene p53 by PCR-SSCP and sequencing methods. 
Our results showed that 21% ( I  1/53) of oral carcinomas 
analyzed carried mutations within the exons 5-8 of the p53 
gene. We have identified I I  single-base pair substitutions 
consisting of 10 mis-sense mutations and one at the splice 
acceptor site, and one deletion mutation invoMng 4 consecutive 
bases. The majority of the base substitutions were transitions (5 
TA to CG and 5 GC to AT), while only one transversion (TA to 
GC) was observed. Probable hot-spots for the mutation induc- 
tion were identified at d o n s  149 and 274, which have not been 
observed before in head-and-neck cancers. The mutational 
spectrum might have originated from base alkylations at gua- 
nine and thymine residues, caused by some al ating agents. 
tobacco-related nitroroarnines in the etiology of oral squamour- 
cell carcinoma. 
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The present results are thus consistent with the T nvolvement of 
Oral squamous-cell carcinoma is relatively uncommon in 
most parts of the world. However, in India, it occupies the top 
rank among male cancers and ranks within the first 5 among 
female cancers (Gupta, 1993). Oral cancers of Indian origin 
thus represent a unique system for studying the role of 
carcinogens, because they are often linked to the tobacco- 
chewing habit. 
The tumor-suppressor gene p53 is the most frequently 
mutated gene in human cancers, where loss of one allele is 
often coupled with a point mutation in the other (Caron de 
Fromentel and Soussi, 1992; Levine et al., 1994). Studies on 
p53 gene mutations in oral cancer from Japan, China, USA, 
Switzerland and Papua New Guinea indicate that thep53 gene 
is mutated in 17 to 63% of the tumors and most of these 
mutations occur in highly conserved regions [exons 5-9 of the 
gene (Sakai and Tsuchida, 1992; Sakai et al., 1992; Changet al., 
1992; Somers et al., 199z Brachman ef al., 1992; Boyle et al., 
1993; Chung et al,, 1993; Zariwala et al., 1993; Thomas et al., 
1994). There are only 2 reports on the mutational profile of 
tobacco-chewing-related oral cancers. Ranasinghe et al. (1993) 
reported no mutation in Sri Lankans when 5 neoplasms 
overexpressing p53 gene were analyzed, while Thomas et al. 
(1994) observed mutations in 17% of 30 tumors from tobacco 
chewers. 
The present study was conducted to determine the muta- 
tional profile in the tumor-suppressor gene p53 in tobacco- 
related oral tumors of Indians. To screen the p53 mutations, 
the DNAs were amplified by PCR and the amplified products 
were subjected to single-strand conformation polymorphism 
(SSCP) analysis, then the SSCP-positive samples were se- 
quenced for identification of the mutations. The results showed 
that 21% of SCCs of the oral cavity had mutations in the p53 
gene. 
MATERIAL AND METHODS 
Patients and tumor samples 
Samples of 53 surgically resected oral squamous-cell carcino- 
mas arising from the cheek (27), tongue (8), alveolus (8), angle 
of mouth (5 ) ,  lips (3), floor of the mouth (1) and palate (1) 
were collected from patients at the Government Rajaji Hospi- 
tal, Madurai, India. The tumors were put in cold PBS and 
immediately transported on ice to the laboratory. They were 
either snap-frozen in liquid nitrogen and stored at -70°C or 
immediately processed for DNA isolation. None of the pa- 
tients had received chemotherapy or radiotherapy prior to 
tumor resection. 
DNA extraction 
High-molecular-weight DNA was prepared from tumor 
tissues by phenol/chloroform extraction (Maniatis et al., 1989). 
PCR and sequencing primers 
Four sets of primers were used to amplify exons 5-8 of the 
p53 gene. The same sets of primers were used for DNA 
sequencing. The sequences of these primers are: 
E5S TGTTCACTTGTGCCCTGCT 
E5A CAGCCCTGTCGTCTCTCCAG 
E6S GCCTCTGATTCCTCACTGAT 
E6A TTAACCCCTCCTCCAGAGA 
E7S ACTGGCCTCATCTTGGGCCT 
E7A TGTGCAGGGTGGCAAGTGGC 
E8S TAAATGGGACAGGTAGGACC 
E8A TCCACCGCTTCTTGTCCTGC 
These primers were selected from the previous study (Sakai 
and Tsuchida, 1992) and obtained by custom ordering from 
Oligos Etc. (Wilsonville, OR). 
Polymerase chain reaction and single-strand conformation 
polymorphism (SSCP) analysis 
Exons 5 to 8 of the p53 gene were PCR-amplified from 
tumor DNAs and mutations were detected by SSCP using a 
6% non-denaturing polyacrylamide gel containing 5% glycerol 
as described previously (Sakai and Tsuchida, 1992). Cell-line 
DNAs from HOC605, NA, Ca922 and ZA (Sakai and Tsu- 
chida, 1992) were used as positive controls. 
Direct sequencing 
Abnormal bands detected by SSCP were excised from the 
dried gel, placed in 50 p1 of distilled water and incubated at 
80°C for 30 min. An aliquot (5 pl of the supernatant) was then 
used for PCR. The double-stranded PCR products were 
purified from agarose gel by electrophoretically transferring 
the DNA band to Whatman DE-81 paper, then eluting with 1.5 
M NaCI. The DNA sequence of the PCR product was 
determined by using a PRISM Ready Reaction Dye Deoxy 
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster 
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City, CA). The gel electrophoresis, data collection and analysis 
were performed on an Applied Biosystems Model 373 A 
automated sequencer. 
RESULTS 
PCRISSCP analysis 
Fifty-three squamous-cell carcinomas of the oral cavity were 
examined for p53 gene mutations. Exons 5-8 of the p53 gene 
were amplified in the presence of a l ~ h a - ~ * P  dCTP by PCR and 
analyzed by SSCP. DNA fragments showing electrophoretic 
mobility shifts in comparison to those of normal cell DNAs 
were scored as positive for mutation. Human placental and 
peripheral lymphocyte DNAs were used as normal controls 
and HOC605, NA, Ca922 and ZA DNAs as positive controls of 
mutated fragments of exons 5, 6, 7 and 8, respectively, and 
included in SSCP analyses (Sakai and Tsuchida, 1992). In 
comparison with normal cell DNAs, 11 tumors showed a 
mobility shift (Figs. 1 and 2a). Some PCR-amplified fragments 
of tumor DNAs showed mobilities similar to those of wild-type 
controls with varying intensities. The amplified DNAs showing 
only mutant bands were used directly for sequencing. Wher- 
ever additional bands corresponding to normal cell DNAs 
were also present, the mutant fragment was excised and the 
DNA from the band was reamplified and subsequently used 
for sequencing. A representative sequence analysis is shown in 
Figure 2b. 
FIGURE 1- PCR-SSCP analysis of tumor DNAs. (a) Exon 5;  (6) 
Exon 6; (c) Exon 7; (d) Exon 8. DNAs from tumors are indicated 
by T followed by tumor number. P, placental DNA. HOC605, NA 
and ZA are DNA from cell lines having mutatedp53 genes of 126 
Tyr > Stop, 220 Tyr > His, and 279 Gly > Glu, respectively. Two 
major unmarked bands shown in (I and c, and bands corresponding 
to placental DNA shown in d, are those from the wild-type 
sequence in tumor DNAs. 
Determination of mutated sequences 
Direct sequencing of SSCP-positive samples revealed sev- 
eral base-substitution mutations and a deletion mutation 
(Table I). Five tumor samples had mutations in exon 5: these 
mutations consisted of 3 different base substitutions in codon 
143 (GTG to ATG), codon 149 (TCC to CCC) and codon 181 
(CGC to CAC). Only one tumor had a mutation in exon 6 in 
which a TAT to GAT conversion was observed in codon 205. 
Two different mutations in exon 7, one in codon 237 (ATG to 
ATA) and the other in the splice acceptor site (AG/GT to 
AG/AT) were observed in 2 different tumors (Table I). Four 
samples had mutations in emn 8: in 2 cases G l T  was converted to 
GCT in codon 274, in 1 case CGT was changed to TGT in codon 
273, and in 1 case a 4-bp deletion, involving the last 2 bases of 
codon 273 and first 2 bases of codon 274, was seen. 
Although the frequency of p53 mutations in all oral tumors, 
taken together, was low (21%), it is to be noted that when a 
site-wise comparison was made, tumors from the angle of 
mouth and alveolus showed a higher frequency (40-50%) of 
mutations (Table 11). 
The sequence alterations summarized in Table I show that 
the mutations and the deletion were found between codons 
143 and 274, corresponding to exons 5 through 8 of the p53 
gene. One tongue tumor (T18) showed a double mutation: one 
in codon 149 and the other in codon 274. Three tumors-from 
tongue (T18), cheek (T22), and alveolus (T80)-had muta- 
tions in the same position of exon 5 ,  codon 149 (TCC to CCC). 
Similarly, a mutation in exon 8, codon 274 (G?T to GCT') was 
common to a tumor of tongue (T18) and a tumor of the angle 
of mouth (T31). 
DISCUSSION 
Mutations in the p53 gene are the most frequently observed 
genetic changes in human cancers (Caron de Fromentel and 
Soussi, 1992; Levine et al., 1994). Our results showed that 21% 
(11/53) of oral carcinomas analyzed carried mutations within 
exons 5-8 of thep53 gene. It is to be noted that we could have 
missed a few mutations since we sequenced only the SSCP- 
positive DNAs. We identified 12 mutations in 11 carcinomas, 
and most (11/12) of the mutations were single-base substitu- 
tions of transitions at either AT or GC pairs (Table I). This 
type of mutagenesis is reminiscent of the activity of alkylating 
agents such as ethyl nitrosourea (Bronstein et al., 1991), which 
can produce 06-alkylguanine and 04-4alkylthymine. Further, 
9/11 transitions were G and T on the coding strand where 
repair was reported to be slower than on the template strand 
(Bohr, 1991). Overall, the spectrum of the p53 gene is 
consistent with the involvement of tobacco-related nitroso- 
amines in the etiology of oral squamous-cell carcinoma (Hoff- 
man and Hecht, 1985). In fact, most (8/11) of the cases with 
identified mutations were from patients with a long-term 
(more than 5 years) habit of tobacco chewing (Table I). Since 
high frequencies of transition mutations were also noted in 
studies of oral squamous-cell carcinomas in Japan (Hirano ef 
al., 1995), other factors such as tobacco smoking and alcohol 
consumption could have caused similarities in the mutational 
spectrum. It has been reported that there were no correlation 
of alcohol drinking with thep53 mutation frequency in cancers 
of the upper aero-digestive tract (Franceschi et al., 1995). The 
mutations observed by us may not be due to the carcinogenic 
hydrocarbons of tobacco smoke, since these chemicals were 
shown to be implicated in transversions and, in our analysis, all 
mutations except one were transitions. 
Relatively low frequencies of p53 gene mutation were 
observed in developing countries, where 79% of total oral 
cancers in the world occur, suggesting the involvement of other 
genes in the genesis of oral cancer in addition to the p53 
mutation. Even in our cases derived mostly from the tobacco- 
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FIGURE 2 - Sequence analysis of the T-22 Exon 5 DNA. (a) PCR-SSCP analysis showing mobility shift in tumor DNA. The fragment 
indicated by the arrow was subjected to sequencing. N indicates DNA from normal tissue: T, DNA from tumor. (b) ABI 
electropherograms of normal and tumor DNA sequences. Mis-sense mutation at codon 149 is shown. This T + C transition resulted in a 
ser-pro alteration. 
TABLE I -p53 MUTATIONS IN ORAL CANCERS OF INDIANS 
Amino- acid 
change Mutated codon 
Tumor Primary Chewing TNM 
number he'sex site history stage' 
Exon 5 
T-18 
T-22 
T-32 
T-59 
T-80 
Exon 6 
T-41' 
Exon 7 
T-65 
T-73' 
Exon 8 
T-18 
T-3 1 
T-39 
T-69 
2.1 .o 
3.1.0 
149 TCC - CCC 
149 TCC - CCC 
181 CGC - CAC 
143 GTG -ATG 
149 TCC - CCC 
45/F Tongue 
- Cheek 
50/M Cheek 
55/F Cheek 
50/F Alveolus 
No 
Yes 
Yes 
Yes 
Yes 
ser-pro F-y!: 
v a L e t  
ser-pro 
- 
4.1.0 
4.1.0 
60/M Alveolus Yes 4.1.0 205 TAT -GAT tyr-asp 
47/M Angle of mouth 
45/F Alveolus 
No 
Yes 
4.0.0 
4.1 .O 
AGIGT E7 S . A  
237 ATG - ATA 
- 
met-ile 
45/F Ton ue 
50/M An& of mouth 
60/F Alveolus 
45/F Cheek 
No 
Yes 
Yes 
Yes 
2.1.0 
4.3.0 
4.3.0 
- 
274 GTT - GCT 
274 GTT - GCT 
273 CGT - TGT 
4 base pair deletion 
Val-ala 
Val-ala 
arg-cys 
- 
'Mutations identical to those in T-41 and T-73 were reported b others, while the other mutations 
have not hitherto been re orted in head-and-neck cancers {Cariello et aL, 1994).-*Data not 
available or not applicable.- ! TNM, tumor-nodes-metastasis. 
India (Saranath et al., 1991). Our preliminary results with the 
same samples also showed a relatively high incidence (32%) of 
ras mutation. It should also be noted that, when tumor samples 
were dissected, no previous therapeutic intervention with 
either radiation or chemicals had occurred in these cases, in 
contrast to those examined in developed countries. 
TABLE II - ASSOCIATION OFo53 MUTATIONS WITH TUMOR SITES 
Total number Number of tumors 
of tumors analyzed with mutations Tumor site 
Cheek 27 
Tongue 8 
Alveolus 8 
Angle of mouth 5 
Lips 3 - 
- Floor of mouth 1 
Palate 1 - 
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and betel-quid-chewing population of India, the observed 
incidence of p53 mutation was 21%, which is relatively low. 
Thus, tobacco-related nitrosamines, which could explain the 
mutational profile observed in the p53 gene, may also cause 
mutations in other cancer-related genes such as ras, since it has 
been shown that ras mutations in oral cancers were low in 
Japan (Sakai et al., 1992), Europe (Rumsby et al., 1990), and 
the USA (Somerset al., 1990) while they were relatively high in 
MUNIRAJAN ETAL. 
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